The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy

Clinical Endocrinology

Volumn 79, Issue 3, 2013, Pages 437-442

  Mitchell, Anna L ^a   Gan, Earn H ^a   Morris, Margaret ^b   Johnson, Kim ^b   Neoh, Christopher ^b   Dickinson, A Jane ^b   Perros, Petros ^a,b   Pearce, Simon H S ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; CHLORPHENIRAMINE; HYDROCORTISONE; LEVOTHYROXINE; LIOTRIX; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISOLONE; RITUXIMAB; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; B CELL DEPLETION THERAPY; B LYMPHOCYTE; CASE STUDY; CHILL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; EDEMA; ENDOCRINE OPHTHALMOPATHY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPOTHYROIDISM; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; THYROID FUNCTION TEST; TREATMENT RESPONSE;

EID: 84880802152     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12141     Document Type: Article

References (25)

1. Bartalena, L., &, Tanda, M.L., (2009) Clinical practice. Graves' ophthalmopathy. New England Journal of Medicine, 360, 994-1001.
2. Brent, G.A., (2008) Clinical practice. Graves' disease. New England Journal of Medicine, 358, 2594-2605.
3. Bahn, R.S., (2010) Graves' ophthalmopathy. New England Journal of Medicine, 362, 726-738.
4. Smith, T.J., (2010) Pathogenesis of Graves' orbitopathy: a 2010 update. Journal of Endocrinological Investigation, 33, 414-421.
5. Wiersinga, W.M., &, Prummel, M.F., (2001) Pathogenesis of Graves' ophthalmopathy-current understanding. Journal of Clinical Endocrinology and Metabolism, 86, 501-503.
6. Terwee, C., Wakelkamp, I., Tan, S., et al,. (2002) Long-term effects of Graves' ophthalmopathy on health-related quality of life. European Journal of Endocrinology, 146, 751-757.
7. Mourits, M.P., Prummel, M.F., Wiersinga, W.M., et al,. (1997) Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology, 47, 9-14.
8. Werner, S.C., (1977) Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. Journal of Clinical Endocrinology and Metabolism, 44, 203-204.
9. Bartalena, L., Krassas, G.E., Wiersinga, W., et al,. (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active graves' orbitopathy. J Clin Endocrinol Metab, 97, 4454-4463.
10. Bartalena, L., (2010) What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail? Clinical Endocrinology, 73, 149-152.
11. Bartalena, L., Baldeschi, L., Dickinson, A.J., et al,. (2008) Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid: Official Journal of the American Thyroid Association, 18, 333-346.
12. Reff, M.E., Carner, K., Chambers, K.S., et al,. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435-445.
13. El Fassi, D., Nielsen, C.H., Hasselbalch, H.C., et al,. (2006) Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid: Official Journal of the American Thyroid Association, 16, 709-710.
14. Khanna, D., Chong, K.K., Afifiyan, N.F., et al,. (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology, 117, 133-139 e132.
15. Salvi, M., Vannucchi, G., Campi, I., et al,. (2007) Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology, 156, 33-40.
16. Salvi, M., Vannucchi, G., Campi, I., et al,. (2006) Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology, 154, 511-517.
17. Silkiss, R.Z., Reier, A., Coleman, M., et al,. (2010) Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg, 26, 310-314.
18. Vannucchi, G., Campi, I., Bonomi, M., et al,. (2010) Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clinical and Experimental Immunology, 161, 436-443.
19. Krassas, G.E., Stafilidou, A., &, Boboridis, K.G., (2009) Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clinical Endocrinology, 72, 853-855.
20. Salvi, M., Vannucchi, G., Curro, N., et al,. (2012) Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Archives of Ophthalmology, 130, 122-124.
21. El Fassi, D., Nielsen, C.H., Bonnema, S.J., et al,. (2007) B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. Journal of Clinical Endocrinology and Metabolism, 92, 1769-1772.
22. Heemstra, K.A., Toes, R.E., Sepers, J., et al,. (2008) Rituximab in relapsing Graves' disease, a phase II study. European Journal of Endocrinology, 159, 609-615.
23. El Fassi, D., Banga, J.P., Gilbert, J.A., et al,. (2009) Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clinical Immunology: The Official Journal of the Clinical Immunology Society, 130, 252-258.
24. Weetman, A.P., McGregor, A.M., &, Hall, R., (1984) Evidence for an effect of antithyroid drugs on the natural history of Graves' disease. Clinical Endocrinology, 21, 163-172.
25. Heyes, C., Nolan, R., Leahy, M., et al,. (2012) Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis. Australasian Journal of Dermatology, 53, e1-e4.